New proprietary monitoring devices can help the 157 Million US Adults suffering from chronic conditions,…
Lenovo And Dallas Cowboys Multi-Year Partnership Brings Cutting-Edge Hardware Technology to Dallas Cowboys Organization Cowboys…
Erinn King joins the Boston-based fixed income manager to drive the firm’s growth strategy and…
Nicholas Holmes appointed portfolio manager and senior analyst CHICAGO–(BUSINESS WIRE)–Duff & Phelps Investment Management Co.,…
Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of…
Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of…
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types…
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types…
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after…
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after…
Preclinical data describes a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor active against key oncogenic ErbB2 mutations…
Preclinical data describes a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor active against key oncogenic ErbB2 mutations…
Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with…
Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with…
INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target…
INB-300, a gamma-delta T cell chimeric antigen receptor (CAR) platform, demonstrated the ability to target…
IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic…
IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic…
BRISBANE, Calif., April 17, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage…
BRISBANE, Calif., April 17, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage…